The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy
Abstract
Summary: Omalizumab is a humanized monoclonal anti‐IgE antibody developed for the treatment of allergic disease, with established efficacy in patients with moderate‐to‐severe allergic asthma and in patients with intermittent (seasonal) and persistent (perennial) allergic rhinitis (AR). Omalizumab is known to result in a marked reduction in serum levels of free IgE and down‐regulation of IgE receptors on circulating basophils. Recent work has shed further light on its mechanism of action, showing significant and profound reductions in tissue (nasal and bronchial) eosinophils and in bronchial IgE+ cells (mast cells), as well as T cells and B cells. Omalizumab treatment was also shown to be associated with down‐regulation of IgE receptors on circulating (precursor) dendritic cells, suggesting that blocking IgE may inhibit more chronic aspects of allergic inflammation involving T cell activation. Further work with omalizumab demonstrated it to have important benefits in patients with poorly controlled asthma despite high‐dose inhaled corticosteroid therapy, and analysis of clinical data suggests that the patients who are the best ‘responders’ to anti‐IgE treatment are those with asthma at the more severe end of the spectrum. Notably, systemic anti‐IgE therapy with omalizumab has been shown to improve symptoms, quality of life and disease control (asthma exacerbations) in patients with concomitant asthma and persistent AR. These impressive clinical data and the studies elucidating the anti‐inflammatory profile of omalizumab also serve to emphasize the fundamental importance of IgE in the pathogenesis of allergic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Self-citationBusse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Self-citationMeasuring Quality of Life in Asthma
Juniper, E. F., Guyatt, G. H., Ferrie, P. J., & Griffith, L. E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.832 · Cited by 887
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
MacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
JUNIPER, E. F., & GUYATT, G. H. (1991) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1991.tb00807.x · Cited by 811
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Self-citation
Cited by
The development of allergic inflammation
Galli, S. J., Tsai, M., & Piliponsky, A. M. (2008) · Nature · doi:10.1038/nature07204 · Cited by 1,839
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Treatment strategies for allergy and asthma
Holgate, S. T., & Polosa, R. (2008) · Nature Reviews Immunology · doi:10.1038/nri2262 · Cited by 691
Self-citationNew developments in FcεRI regulation, function and inhibition
Kraft, S., & Kinet, J.-P. (2007) · Nature Reviews Immunology · doi:10.1038/nri2072 · Cited by 579
Metadata
- Authors
- Holgate, S. T., Djukanović, R., Casale, T., & Bousquet, J.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 35
- Issue
- 4
- Pages
- 408-416
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2142637315
- Cited by
- 254
- References
- 45
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy. https://app.cochat.ai/papers/10.1111/j.1365-2222.2005.02191.x
- The paper
- Holgate, S. T., Djukanović, R., Casale, T., & Bousquet, J. (2005). Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2005.02191.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.